<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360269</url>
  </required_header>
  <id_info>
    <org_study_id>R21DA018221</org_study_id>
    <secondary_id>R21DA018221</secondary_id>
    <nct_id>NCT00360269</nct_id>
    <nct_alias>NCT00227851</nct_alias>
  </id_info>
  <brief_title>Atomoxetine Treatment for ADHD and Marijuana Dependence</brief_title>
  <official_title>Atomoxetine Treatment for ADHD and Marijuana Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine if atomoxetine treatment combined with motivational
      enhancement therapy is effective in reducing marijuana use in adult individuals with
      attention-deficit hyperactivity disorder and marijuana dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether the medication atomoxetine, or Strattera,
      plus 3 sessions of counseling can help people to reduce the symptoms of ADHD and to help cut
      back on their marijuana use. Participation in the study is approximately 12 weeks of
      medication treatment and doctor's visits once a week. The first 2 visits consist of
      evaluations to determine if you qualify to participate. These visits are approximately 2-3
      hours long and will include questions about your past and present substance use, psychiatric
      history, a routine physical exam, bloodwork, and paper and pencil questionnaires about your
      marijuana use. Once you are enrolled in the study, visits are typically 30 minutes long, once
      a week. The one-on-one counseling sessions regarding marijuana use are 1 hour long and you
      will have 3 sessions throughout the study. If you qualify for this study, you will receive
      either atomoxetine, or a placebo (sugar pill). Study participants will have a 50% chance of
      receiving atomoxetine. Atomoxetine is a non-stimulant, commonly used to treat ADHD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Week 12 Self-reported Use</measure>
    <time_frame>One week (study week 12)</time_frame>
    <description>Participants' self-report of mean frequency of use of marijuana during week 12 of the study was assessed using a Time-Line Follow-Back.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported Longitudinal Use</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants' self-report of mean frequency of use of marijuana from baseline through week 12 visit of the study was assessed using a Time-Line Follow-Back.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Drug Screens</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants submitted a urine sample weekly. Percentage of marijuana positive urine samples were calculated per group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wender-Reimherr Adult Attention Deficit Disorder Scale</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The WRAADDS is intended to measure the severity of ADHD symptoms in adults. It measures symptoms in seven categories: attention difficulties, hyperactivity/restlessness, temper, affective lability, emotional over-reactivity, disorganization, and impulsivity. The scale rates individual items from 0-2 (0=not present, 1=mild, 2=clearly present), with a minimum score of 0 and maximum score of 46. Reported here is change from Baseline to Week 12 (or LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression, Improvement Scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Clinical Global Impression - Improvement scale (CGI-I) was used to assess improvement in ADHD symptoms during study participation. CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Marijuana Abuse</condition>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atomoxetine plus Motivational Enhancement Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus Motivational Enhancement Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>25 to 100 mg daily</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Motivational enhancement therapy</intervention_name>
    <description>Three sessions</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>MET</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>25 to 100 mg daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy men and women, 18 to 65 years of age

          2. Meet DSM-IV criteria for marijuana dependence

          3. Meet DSM-IV criteria for current ADHD, determined by a clinical interview and
             confirmed by semi-structured interview with the Conners' Adult ADHD Diagnostic
             Interview for DSM-IV (CAAR-D; Conners et al, 1999)

          4. ADHD symptom severity indicated by a score of 12 or greater on the Wender-Reimherr
             Adult Attention Deficit Disorder Scale

          5. ADHD symptoms must be corroborated by a second informant on either current symptoms
             (by a significant other or close friend) or childhood symptoms (by a parent or older
             sibling)

          6. All subjects will agree to and sign a written, IRB-approved informed consent

          7. Subjects must live within a 60-mile radius of Charleston, SC, to facilitate study
             visit compliance

        Exclusion Criteria:

          1. Individuals meeting DSM-IV dependence for a substance other than marijuana with the
             exception of nicotine and caffeine. Dependence on nicotine and caffeine will be
             allowed since dependence on these substances commonly co-occurs with marijuana
             dependence and excluding these individuals would compromise study recruitment

          2. Individuals meeting DSM-IV criteria for a lifetime history of schizophrenia or another
             non-affective psychotic disorder or bipolar disorder, since these patients will most
             likely be taking other psychotropic medications and often require intensive
             psychiatric care

          3. Individuals meeting DSM-IV criteria for current major depressive disorder or eating
             disorder, since these individuals will likely require treatment with psychotropic
             medications. Subjects may meet criteria for a minor mood disorder (dysthymia) and for
             anxiety disorders. The inclusion of subjects with these disorders will be allowed as
             they commonly co-exist among patients with marijuana dependence (Stephens et al, 1993)

          4. Individuals who present significant suicidal risk

          5. Individuals with significant cognitive impairment as measured by a score of less than
             26 on the Mini-Mental Status Exam, as they may be unable to understand the informed
             consent, comply with study protocol, or accurately complete assessments

          6. Individuals currently receiving stimulants, benzodiazepines, antidepressant or
             antipsychotic medications, as these medications could confound the effects of
             atomoxetine treatment

          7. Individuals currently receiving psychotherapy focusing on reducing marijuana use or on
             ADHD symptoms, as this could confound the effects of atomoxetine treatment.
             Participation in 12-step programs will be allowed

          8. Pregnant or nursing women, or women who refuse to use adequate birth control, as
             atomoxetine has not been approved for use in pregnancy

          9. Individuals without stable housing, as contacting these individuals would be difficult

         10. Individuals with major medical illnesses (e.g., HIV, renal failure, unstable angina,
             chronic obstructive pulmonary disease, infectious hepatitis)

         11. Patients with hypertension (defined as having blood pressure greater than 140/90
             measured on 3 or more occasions), as atomoxetine treatment can be associated with
             increases in blood pressure

         12. Patients with evidence of hepatic insufficiency, as atomoxetine requires hepatic
             metabolism

         13. Patients with urinary hesitancy or urinary hesitation, as atomoxetine has been
             associated with some urinary hesitation in clinical trials

         14. Individuals who, in the investigators' opinion, would not be able to comply with study
             procedures, such as individuals unable to reliably present for intake appointments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee L McRae, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2006</study_first_submitted>
  <study_first_submitted_qc>August 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2006</study_first_posted>
  <results_first_submitted>November 7, 2011</results_first_submitted>
  <results_first_submitted_qc>March 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2012</results_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Aimee McRae-Clark</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited between November 2005 and June 2008 primarily through media advertisements and fliers</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atomoxetine</title>
          <description>Flexible dose up to 100mg/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Flexible dose up to 100mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atomoxetine</title>
          <description>Flexible dose up to 100mg/day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Flexible dose up to 100mg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.4" spread="10.0"/>
                    <measurement group_id="B2" value="30.4" spread="13.0"/>
                    <measurement group_id="B3" value="29.9" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Self-reported Longitudinal Use</title>
        <description>Participants' self-report of mean frequency of use of marijuana from baseline through week 12 visit of the study was assessed using a Time-Line Follow-Back.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Flexible dose up to 100mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dose up to 100mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Longitudinal Use</title>
          <description>Participants' self-report of mean frequency of use of marijuana from baseline through week 12 visit of the study was assessed using a Time-Line Follow-Back.</description>
          <units>Percentage of days used</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" spread="31.5"/>
                    <measurement group_id="O2" value="68.1" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimated Week 12 Self-reported Use</title>
        <description>Participants' self-report of mean frequency of use of marijuana during week 12 of the study was assessed using a Time-Line Follow-Back.</description>
        <time_frame>One week (study week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Flexible dose up to 100mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dose up to 100mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Week 12 Self-reported Use</title>
          <description>Participants' self-report of mean frequency of use of marijuana during week 12 of the study was assessed using a Time-Line Follow-Back.</description>
          <units>Times per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread=".34"/>
                    <measurement group_id="O2" value="1.84" spread=".34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Drug Screens</title>
        <description>Participants submitted a urine sample weekly. Percentage of marijuana positive urine samples were calculated per group.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Flexible dose up to 100mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dose up to 100mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Drug Screens</title>
          <description>Participants submitted a urine sample weekly. Percentage of marijuana positive urine samples were calculated per group.</description>
          <units>Percentage of positive UDS</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3"/>
                    <measurement group_id="O2" value="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wender-Reimherr Adult Attention Deficit Disorder Scale</title>
        <description>The WRAADDS is intended to measure the severity of ADHD symptoms in adults. It measures symptoms in seven categories: attention difficulties, hyperactivity/restlessness, temper, affective lability, emotional over-reactivity, disorganization, and impulsivity. The scale rates individual items from 0–2 (0=not present, 1=mild, 2=clearly present), with a minimum score of 0 and maximum score of 46. Reported here is change from Baseline to Week 12 (or LOCF).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Flexible dose up to 100mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dose up to 100mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Wender-Reimherr Adult Attention Deficit Disorder Scale</title>
          <description>The WRAADDS is intended to measure the severity of ADHD symptoms in adults. It measures symptoms in seven categories: attention difficulties, hyperactivity/restlessness, temper, affective lability, emotional over-reactivity, disorganization, and impulsivity. The scale rates individual items from 0–2 (0=not present, 1=mild, 2=clearly present), with a minimum score of 0 and maximum score of 46. Reported here is change from Baseline to Week 12 (or LOCF).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.05" spread="10.96"/>
                    <measurement group_id="O2" value="-11.05" spread="7.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression, Improvement Scale</title>
        <description>The Clinical Global Impression - Improvement scale (CGI-I) was used to assess improvement in ADHD symptoms during study participation. CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Flexible dose up to 100mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dose up to 100mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression, Improvement Scale</title>
          <description>The Clinical Global Impression - Improvement scale (CGI-I) was used to assess improvement in ADHD symptoms during study participation. CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="0.68"/>
                    <measurement group_id="O2" value="3.26" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atomoxetine</title>
          <description>Flexible dose up to 100mg/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Flexible dose up to 100mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hot/cold flashes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinus/allergies/flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/lightheaded</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety/depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased urination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size and poor retention</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Aimee McRae-Clark, Pharm.D., BCPP</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-5215</phone>
      <email>mcraeal@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

